Modern opportunities of metabolic health management in patients with obesity and carbohydrate metabolism disorders

• Alexander S. Ametov
• Olga P. P'yanykh
• Anna O. Nevolnikova

Abstract

Due to the formation of chronic inflammation and insulin resistance obesity increases the risk of various diseases. There are various theories of the occurrence of insulin resistance. According to them inflammation, dysfunction of mitochondria, hyperinsulinemia and lipotoxicity are believed to play a crucial role, and, therefore, are given great attention. The important problem is the lack of a universal pathogenetic mechanism for the development of insulin resistance, which combines all of these theories. Moreover, none of the listed concepts or points of view has led to an improvement and increase in the effectiveness of the treatment of carbohydrate metabolism disorders. In this regard, the use of fixed dose combination drugs, that can act on different pathogenetic triggers of the development of polymorbid pathology in obesity, can be a key step in compensating for pathological processes and achieving metabolic health.

Keywords:obesity, insulin resistance, metformin, sibutramine, Reduxine® Forte

References

1. https://www.who.int/gho/ncd/risk_factors/overweight/en/ (date of access: 08.03.2020)

2. Ametov A.S., Prudnikova M.A. Obesity and type 2 diabetes: modern aspects of pharmacotherapy. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2016; (4): 16-21. (in Russian)

3. Mathis D. Immunological goings-on in visceral adipose tissue. Cell Metab. 2013; 17 (6): 851-9. doi: 10.1016/j.cmet.2013.05.008

4. Mothe-Satney I., Filloux C., Amghar H., Pons C., Bourlier V., Galitzky J., et al. Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice. Diabetes. 2012; 61 (9): 2311-9. doi: 10.2337/db11-1455

5. Kurokawa J., Nagano H., Ohara O., Kubota N., Kadowaki T., Arai S., et al. Apoptosis inhibitor of macrophage (AIM) is required for obesity-associated recruitment of inflammatory macrophages into adipose tissue. Proc Natl Acad Sci USA. 2011; 108 (29): 12072-7. doi: 10.1073/pnas.1101841108

6. Pitsavos C., Tampourlou M., Panagiotakos D.B., Skoumas Y., Chrysohoou C., Nomikos T., et al. Association between low-grade systemic inflammation and type 2 diabetes mellitus among men and women from the ATTICA Study. Rev Diabet Stud. 2007; 4 (2): 98-104.

7. Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr. Diab. Rep. 2006; 6: 177-81.

8. Yang H., Youm Y.H., Vandanmagsar B., Ravussin A., Gimble J.M., Greenway F., et al. Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance. J Immunol. 2010; 185 (3): 1836-45.

9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-53.

10. Smirnova O.M. The role of metformin in the modern strategy of treatment and prevention of type 2 diabetes mellitus. Sakharni Diabet [Diabetes Mellitus]. 2010; (3): 83-90. (in Russian)

11. Ruyatkina L.A., Ruyatkin D.S.Multidimensional effects of metformin in patients with type 2 diabetes. Sakharni Diabet [Diabetes Mellitus]. 2017; 20 (3): 210-9. (in Russian)

12. Nedosugova L.V. Current place of metformin in the treatment of type 2 diabetes // Terapiya [Therapy]. 2015; (4): 24-31. (in Russian)

13. Wojcicka G., Jamroz-Wisniewska A., Czechowska G., et al. The paraoxonase 1 (PON 1), platelet-activating factor acetylohydrolase (PAF-AH) and dimethylarginine dimethylaminohydrolase (DDAH) activity in the metformin treated normal and diabetic rats. Eur J Pharmacol. 2016; 789: 187-94. doi: 10.1016/j.ejphar.2016.07.034

14. Bekezin V.V. Oxidative stress associated with obesity, an early marker of metabolic syndrome in children and adolescents (review article). Smolenskiy meditsinskiy almanakh [Smolensk Medical Almanac]. 2016; (3): 6-13. (in Russian)

15. Zhou Z., Tang Y., Jin X., et al. Metformin inhibits advanced glycation end products-induced inflammatory response in murine macrophages partly through AMPK activation and RAGE/NFkappaB pathway suppression. J Diabetes Res. 2016; 2016. 4847812. doi: 10.1155/2016/4847812

16. Urakov A.L., Gurevich K.G., Sorokina I.A., et al. Metformin and vildagliptin combination: a new approach of endothelial nitric oxide synthase activity regulation and metabolism in diabetes mellitus type 2. Obzory po klinicheskoy farmakologii i lekarstvennoy terapii [Reviews on Clinical Pharmacology and Drug Therapy]. 2018; 16 (2): 5-12. doi: 10.17816/RCF1625-12 (in Russian)

17. Rodionov R.N., Blokhin I.O., Galagudza M.M., et al. The emerging role of asymmetric dimethylarginine in cardiovascular disease. Arterial’naya Gipertenziya [Arterial Hypertension]. 2008; 14 (4): 306-14. (in Russian)

18. Bestermann W.H.Jr. The ADMA-metformin hypothesis: linking the cardiovascular consequences of the metabolic syndrome and type 2 diabetes. Cardiorenal Med. 2011; 1 (4): 211-9. doi: 10.1159/000332382

19. Tsai C.M., Kuo H.C., Hsu C.N., et al. Metformin reduces asymmetric dimethylarginine and prevents hypertension in spontaneously hypertensive rats. Transl Res. 2014; Vol. 164 (6): 452-9. doi: 10.1016/j. trsl.2014.07.005

20. Shestakova E.A. Second line therapy in type 2 diabetes: legacy effect activation. Sakharni Diabet [Diabetes Mellitus]. 2017; 20 (5): 35662. (in Russian)

21. Jadhav S., Ferrell W., Greer I.A., Petrie J.R., Cobbe S.M., Sattar N. Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2006; 48 (5): 956-63.

22. Maruthur N.M., Tseng E., Hutfless S., Wilson L.M., Suarez-Cuervo C., Berger Z., et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016; 164 (11): 740-51.

23. Meaney E., Vela A., Samaniego V., Meaney A., Asbun J., Zempoalteca J.C., et al. Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin Exp Pharmacol Physiol. 2008; 35 (8): 895-903.

24. Luo F., Das A., Chen J., Wu P., Li X., Fang Z. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovasc Diabetol. 2019; 18. https://doi.org/10.1186/s12933-019-0860-y

25. Li S.N., Wang X., Zeng Q.T., Feng Y.B., Cheng X., Mao X.B., et al. Metformin inhibits nuclear factor kappaB activation and decreases serum high-sensitivity C-reactive protein level in experimental atherogenesis of rabbits. Heart Vessels. 2009; 24 (6): 446-53.

26. Luo F., Guo Y., Ruan G.Y., Long J.K., Zheng X.L., Xia Q., et al. Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet. Sci Rep. 2017; 7 (1): 2169. doi: 10.1038/s41598-017-02080-w

27. Davis B.J., Xie Z., Viollet B., Zou M.H. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes. 2006; 55 (2): 496-505.

28. Dong Y., Zhang M., Liang B., Xie Z., Zhao Z., Asfa S., et al. Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. Circulation. 2010; 121 (6): 792-803.

29. Eriksson L., Nystrom T. Activation of AMP-activated protein kinase by metformin protects human coronary artery endothelial cells against diabetic lipoapoptosis. Cardiovasc Diabetol. 2014; 13. 152.

30. Luo F., Guo Y., Ruan G., Li X. Metformin promotes cholesterol efflux in macrophages by up-regulating FGF21 expression: a novel antiatherosclerotic mechanism. Lipids Health Dis. 2016; 15: 109.

31. Malin S.K., Kashyap S.R. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014; 21 (5): 323-9. doi: 10.1097/MED.0000000000000095

32. Arterburn D.E., Crane P.K., Veenstra D.L. The efficacy and safety of sibutramine for weight loss. A systematic review. Arch Intern Med. 2004; 164 (9): 994-1003.

33. Cuellar G.E., Ruiz A.M., Monsalve M.C., Berber A. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res. 2000; 8 (1): 71-82.

34. Gokcel A., Gumurdulu Y., Karakose H., Melek Ertorer E., Tanaci N., BascilTutuncu N., et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab. 2002; 4 (1): 49-55.

35. Vosnakis C., Georgopoulos N.A., Armeni A.K., Papadakis E., Roupas N.D., Katsikis I., et al. Sibutramine administration decreases serum anti-mdllerian Hormone (AMH) kevels in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2012; 163 (2): 185-9. doi: 10.1016/j.ejogrb.2012.04.014

36. Ametov A.S., Chernikova N.A., Abdulkadirova F.R., Pokrovskaya R.A., Alferova O.Yu. Role of lipotoxicity in achieving glycemic control in patients with diabetes type 2 and obesity. Meditsinskiy sovet [Medical Council]. 2013; (6): 84-91. (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)